Transmucosal Nasal Drug Delivery: Systemic Bioavailability of ...

More documents

Recommendations

Info

11 References Cote, C.J., Md, I.T. Cohen, S.M.D. Suresh, M.M.D. Rabb, J.B. Rose, B. Weldon, M.D. Craig, P.J. Davis, G.B. Bikhazi, H.W. Karl, K.A. Hummer, Rn, R.S. Hannallah, K.C.M.S. Khoo and P.M.D. Collins 2002 A Comparison of Three Doses of a Commercially Prepared Oral Midazolam Syrup in Children. [Miscellaneous Article]. Anesthesia & Analgesia 94(1):37-43. Dale, O., R. Hjortkjaer and E.D. Kharasch 2002 Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 46(7):759-70. DAV 2006 Kommentar zur Ph. Eur. 5.4 - Midazolam, Midazolanum 5.4/0936: Deutscher Apotheker Verlag. Davis, M.E. and M.E. Brewster 2004 Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 3(12):1023-35. Davis, P.J., J.A. Tome, F.X. McGowan, Jr., I.T. Cohen, K. Latta and H. Felder 1995 Preanesthetic medication with intranasal midazolam for brief pediatric surgical procedures. Effect on recovery and hospital discharge times. ANESTHESIOLOGY 1995 Jan 82(1):2-5. Davis, S.S. and L. Illum 2003 Absorption enhancers for nasal drug delivery. Clin Pharmacokinet 42(13):1107-28. de Visser, S.J., J.P. van der Post, P.P. de Waal, F. Cornet, A.F. Cohen and J.M. van Gerven 2003 Biomarkers for the effects of benzodiazepines in healthy volunteers. Br J Clin Pharmacol 55(1):39-50. de Voogt, H.J., U. Studer, F.H. Schroeder, J.G. Klijn, M. de Pauw and R. Sylvester 1998 Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or longterm (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer Final analysis of EORTC GU Group Trial 30843. European Urology 33(2):152-158. Denis, D., M.P. Lecart, R. Deroisy, A.M. Jeugmans-Huynen, A. Albert, J.Y. Reginster and P. Franchimont 1989 A years' treatment of Paget's disease of bone using salmon calcitonin via nasal spray. Revue medicale de Liege 44(1):23-7. Dhanda, D.S., W.H. Frey, II, D. Leopold and U.B. Kompella 2005 Approaches for drug deposition in the human olfactory epithelium. Drug Delivery Technology 5(4):64-72. Ding, X. and L.S. Kaminsky 2003 Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 43:149-73. Documed 2006 Arzneimittelkompendium der Schweiz 2006. 27. Auflage, 2006, Deutsche Ausgabe ed. Basel. Dodane, V., M. Amin Khan and J.R. Merwin 1999 Effect of chitosan on epithelial permeability and structure. International Journal of Pharmaceutics 182(1):21-32. Dodane, V. and V.D. Vilivalam 1998 Pharmaceutical applications of chitosan. Pharmaceutical Science & Technology Today 1(6):246-253. Dondeti, P., H. Zia and T.E. Needham 1995 In vivo evaluation of spray formulations of human insulin for nasal delivery. International Journal of Pharmaceutics 122(1-2):91-105. Dondeti, P., H. Zia and T.E. Needham 1996 Bioadhesive and formulation parameters affecting nasal absorption. International Journal of Pharmaceutics 127(2):115-133. Dussy, F.E., C. Hamberg and T.A. Briellmann 2005 Quantification of benzodiazepines in whole blood and serum. Int J Legal Med:1-8. Note for guidance on the investigation of bioavailability and bioequivalence EMEA, Commitee for proprietary medicinal products (CPMP); 2001.Available from http://www.emea.eu.int/pdfs/human/ewp/140198en.pdf Katja Suter-Zimmermann Page 178 of 188 University of Basel, 2008
11 References Erjefalt, J.S., I. Erjefalt, F. Sundler and C.G. Persson 1995 In vivo restitution of airway epithelium. Cell Tissue Res 281(2):305-16. Finkel, J.C., I.T. Cohen, R.S. Hannallah, K.M. Patel, M.S. Kim, K.A. Hummer, S.S. Choi, M. Pena, S.B. Schreiber and G. Zalzal 2001 The effect of intranasal fentanyl on the emergence characteristics after sevoflurane anesthesia in children undergoing surgery for bilateral myringotomy tube placement. Anesth Analg 92(5):1164-8. Fisgin, T., Y. Gurer, N. Senbil, T. Tezic, P. Zorlu, C. Okuyaz and D. Akgun 2000 Nasal midazolam effects on childhood acute seizures. J Child Neurol 15(12):833-5. Fisgin, T., Y. Gurer, T. Tezic, N. Senbil, P. Zorlu, C. Okuyaz and D. Akgun 2002 Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study. J Child Neurol 17(2):123-6. Foley, S. and Q. Hamid 2006 Inflammatory patterns in allergic rhinitis. Clinical & Experimental Allergy Reviews 6(4):91-95. Fösel, C., Grüness, Wilhelm, Gebauer, Probst 1996 Der Einfluss von Midazolam nach intranasaler Gabe auf Spontanatmung und Atemregulation bei Kleinkindern. Anästhesiol. Intensivmed. Notfallmed. Schmerzther. 31:22-25. Fuks, A.B., E. Kaufman, D. Ram, S. Hovav and J. Shapira 1994 Assessment of two doses of intranasal midazolam for sedation of young pediatric dental patients. Pediatr Dent 16(4):301-5. Fukuta, O., R.L. Braham, H. Yanase, N. Atsumi and K. Kurosu 1993 The sedative effect of intranasal midazolam administration in the dental treatment of patients with mental disabilities. Part 1. The effect of a 0.2 mg/kg dose. J Clin Pediatr Dent 17(4):231-7. Fukuta, O., R.L. Braham, H. Yanase and K. Kurosu 1994 The sedative effects of intranasal midazolam administration in the dental treatment of patients with mental disabilities. Part 2: optimal concentration of intranasal midazolam. J Clin Pediatr Dent 18(4):259-65. Fukuta, O., R.L. Braham, H. Yanase and K. Kurosu 1997 Intranasal administration of midazolam: pharmacokinetic and pharmacodynamic properties and sedative potential. ASDC J Dent Child 64(2):89-98. Geldner, G., M. Hubmann, R. Knoll and K. Jacobi 1997 Comparison between three transmucosal routes of administration of midazolam in children. Paediatr Anaesth 7(2):103-9. Gervasi, P.G., V. Longo, F. Naldi, G. Panattoni and F. Ursino 1991 Xenobiotic-metabolizing enzymes in human respiratory nasal mucosa. Biochem Pharmacol 41(2):177-84. Gil-Alegre, M.E., J.A. Bernabeu, M.A. Camacho and A.I. Torres-Suarez 2001 Statistical evaluation for stability studies under stress storage conditions. Farmaco 56(11):877-883. Gilat, E., M. Goldman, E. Lahat, A. Levy, I. Rabinovitz, G. Cohen, R. Brandeis, G. Amitai, D. Alkalai and G. Eshel 2003 Nasal midazolam as a novel anticonvulsive treatment against organophosphate-induced seizure activity in the guinea pig. Arch Toxicol 77(3):167-72. Gizurarson, S. 1993 The relevance of nasal physiology to the design of drug absorption studies. Advanced Drug Delivery Reviews 11(3):329-47. Goepfert, A., Schwab, A., Weber, U. 1996 Die intranasale Gabe von Midazolam (Dormicum) bei Kleinkindern in der Notfallmedizin. Anästhesiol. Intensivmed. Notfallmed. Schmerzther. 31:26-28. Graff, C.L. and G.M. Pollack 2003 P-Glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharm Res 20(8):1225-30. Greiff, L., M. Andersson, C. Svensson, S. Lundin, P. Wollmer and C.G. Persson 1997 Reduced airway absorption in seasonal allergic rhinitis. Am J Respir Crit Care Med 156(3 Pt 1):783-6. Katja Suter-Zimmermann Page 179 of 188 University of Basel, 2008
Page 1:
TRANSMUCOSAL NASAL DRUG DELIVERY Sy
Page 5 and 6:
Acknowledgments At the Hospital Pha
Page 7:
Index EXPERIMENTAL SECTION 5 Projec
Page 11 and 12:
Summary Summary Transmucosal nasal
Page 13:
Summary Project III: In this random
Page 17:
THEORETICAL SECTION
Page 20 and 21:
1. Nasal drug delivery 1.2 Transmuc
Page 22 and 23:
1. Nasal drug delivery 1.3 Challeng
Page 25 and 26:
2. Impact of anatomy and physiology
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
3. Midazolam 3 Midazolam 3.1 Physic
Page 33 and 34:
3. Midazolam 3.2.1 Indications and
Page 35 and 36:
3. Midazolam Administration of high
Page 37 and 38:
3. Midazolam gastrointestinal tract
Page 39 and 40:
4. Compounding of nasal midazolam p
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49:
Page 53 and 54:
5. Project I: Development of prepar
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67:
Page 70 and 71:
6. Project II: Pharmacokinetic of t
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Page 88 and 89:
Page 91 and 92:
7. Project III: Transmucosal nasal
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103:
Page 106 and 107:
8 Overall discussion pharmacokineti
Page 108 and 109:
8 Overall discussion considered as
Page 111:
Appendix
Page 114 and 115:
10 Appendix 10.2 Project I 10.2.1 R
Page 116 and 117:
10 Appendix 10.2.4 Specification: M
Page 118 and 119:
10 Appendix 10.2.6 Specification: C
Page 120 and 121:
10 Appendix Katja Suter-Zimmermann
Page 122 and 123:
10 Appendix 10.2.9 Specification: C
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137: 10 Appendix Katja Suter-Zimmermann
Page 150 and 151: 10 Appendix 10.3.2 Case report form
Page 158 and 159: 10 Appendix Frequency 10.3.5 Intens
Page 160 and 161: 10 Appendix 10.3.7 Serumconcentrati
Page 162 and 163: 10 Appendix Identification midazola
Page 168 and 169: 10 Appendix 10.3.8 Midazolam serum
Page 170 and 171: 10 Appendix 10.3.10 Nasal delivery
Page 174 and 175: 10 Appendix 10.4.3 Flowchart: multi
Page 185: 11 References 11 References Abrams,
Page 189 and 190: 11 References Irie, T. and K. Uekam
Page 191 and 192: 11 References Malinovsky, J.M., C.
Page 193 and 194: 11 References Scheepers, M., B. Sch
Page 195 and 196: 12 Curriculum vitae 12 Curriculum v
show all

Transmucosal Nasal Drug Delivery: Systemic Bioavailability of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?